Imunopharm Files for Shanghai STAR Market IPO, Targeting $550 Million Valuation to Expand CAR-T and CDMO Business

July 12, 2026

VCBeat China

Overview

Chinese biotechnology firm Imunopharm has filed for an Initial Public Offering (IPO) on the Shanghai STAR Market, targeting a valuation of 4 billion RMB (approximately $550 million). The company’s pipeline includes autologous CAR-T, in vivo CAR-T, and allogeneic CAR-T therapies for malignant hematologic diseases, solid tumors, and autoimmune conditions. Notably, its subsidiary Cygenta Biotech operates a CDMO business for cell therapy products like CAR-T, TCR-T, and CAR-NK, with IPO funds expected to fuel R&D and manufacturing capacity expansion. This move underscores the growth and increasing competitiveness of China’s cell and gene therapy sector.

In Depth

Key Findings: Imunopharm Files for Shanghai STAR Market IPO, Aiming for $550 Million Valuation

Imunopharm, an innovative Chinese biotechnology company, has announced its application for an Initial Public Offering (IPO) on the STAR Market (Science and Technology Innovation Board) of the Shanghai Stock Exchange. The company is aiming for a valuation of approximately 4 billion RMB (roughly $550 million) through this IPO. This fundraising is intended to accelerate the development of Imunopharm’s diverse cell and gene therapy pipeline, which includes autologous CAR-T, in vivo CAR-T, and allogeneic CAR-T therapies, thereby strengthening its capabilities for commercializing treatments across a wide range of disease areas such as malignant hematologic diseases, solid tumors, and autoimmune diseases.

Technical & Business Details: Diverse Cell Therapy Pipeline and CDMO Business

Imunopharm’s pipeline spans multiple innovative cell therapy technologies:

**Autologous CAR-T Therapy:** Utilizing a patient’s own T cells to provide personalized cancer treatment.
**In vivo CAR-T Therapy:** A next-generation approach that induces CAR-T cells directly within the body.
**Allogeneic CAR-T Therapy:** Aiming for off-the-shelf product development using donor cells to address manufacturing cost and accessibility challenges.

These pipelines cover disease areas with high unmet needs, from blood cancers to solid tumors and autoimmune diseases. Furthermore, Cygenta Biotech, a subsidiary of Imunopharm, operates a CDMO (Contract Development and Manufacturing Organization) business specializing in cell therapy products like CAR-T, TCR-T, and CAR-NK. This CDMO business provides complex cell therapy manufacturing and quality control services to other biotechnology companies, diversifying Imunopharm’s revenue streams and contributing to the overall strengthening of China’s cell and gene therapy ecosystem.

Background & Industry Context: Rapid Growth of China’s CGT Market

China has rapidly emerged as a leading global player in the cell and gene therapy (CGT) sector, with its market experiencing dramatic growth fueled by strong government support, a vast patient pool, and active R&D initiatives. The STAR Market specifically encourages the listing of technology innovation-focused companies, making it an attractive fundraising venue for advanced biotechnology firms like Imunopharm. Imunopharm’s IPO reflects the current trend of Chinese CGT companies actively pursuing large-scale investments to enhance their competitiveness in the global market. By incorporating a CDMO business, the company has established a shrewd business model that mitigates manufacturing risks for its proprietary pipeline while simultaneously generating revenue from external clients.

Strategic Significance & Outlook: Accelerating R&D and Enhancing International Competitiveness

The capital raised from the IPO will accelerate Imunopharm’s R&D activities, particularly advancing the commercialization of next-generation technologies such as in vivo CAR-T therapy and allogeneic CAR-T therapy. It will also enable further strengthening of the CDMO manufacturing capabilities of its subsidiary, Cygenta Biotech, to meet both domestic and international demand. Imunopharm’s success is expected to contribute to the overall enhancement of China’s CGT industry’s international competitiveness and further increase the presence of Chinese companies in the global cell and gene therapy market. In the long term, these innovative therapies are poised to offer new hope and treatment options to patients worldwide, playing a crucial role in shaping the future of medicine. Attention will be focused on the upcoming listing process and subsequent R&D progress.

Source: https://www.vcbeathealth.com/article/59398

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.